SG11202109830TA - Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics - Google Patents

Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Info

Publication number
SG11202109830TA
SG11202109830TA SG11202109830TA SG11202109830TA SG 11202109830T A SG11202109830T A SG 11202109830TA SG 11202109830T A SG11202109830T A SG 11202109830TA SG 11202109830T A SG11202109830T A SG 11202109830TA
Authority
SG
Singapore
Prior art keywords
pah
therapeutics
viral dna
dna vectors
phenylalanine hydroxylase
Prior art date
Application number
Other languages
English (en)
Inventor
Douglas Anthony Kerr
Phillip Samayoa
Nathaniel Silver
Matthew Chiocco
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of SG11202109830TA publication Critical patent/SG11202109830TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11202109830T 2019-03-13 2020-03-13 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics SG11202109830TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962817771P 2019-03-13 2019-03-13
US201962857514P 2019-06-05 2019-06-05
PCT/US2020/022595 WO2020186150A2 (en) 2019-03-13 2020-03-13 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Publications (1)

Publication Number Publication Date
SG11202109830TA true SG11202109830TA (en) 2021-10-28

Family

ID=72426457

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109830T SG11202109830TA (en) 2019-03-13 2020-03-13 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Country Status (12)

Country Link
US (1) US20230024354A1 (de)
EP (1) EP3938515A4 (de)
JP (1) JP2022525302A (de)
KR (1) KR20210149702A (de)
CN (1) CN113874508A (de)
AU (1) AU2020235121A1 (de)
BR (1) BR112021017852A2 (de)
CA (1) CA3133330A1 (de)
IL (1) IL286283A (de)
MX (1) MX2021011037A (de)
SG (1) SG11202109830TA (de)
WO (1) WO2020186150A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
KR20230066615A (ko) * 2020-09-16 2023-05-16 제너레이션 바이오 컴퍼니 폐쇄형 dna 벡터 및 페닐알라닌 히드록실라아제(pah) 발현을 위한 이의 용도
CN115772503B (zh) * 2022-08-16 2023-10-17 广东省南山医药创新研究院 一种表达pah的基因修饰细胞药物及其制备方法与应用
CN116656740A (zh) * 2023-05-30 2023-08-29 浙江大学 一种腺相关病毒基因治疗载体及其在制备治疗苯丙酮尿症的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2037892B1 (de) * 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modifizierte fatkor-viii- und faktor-ix-gene und vektoren für gentherapie
SG11201806663TA (en) * 2016-03-03 2018-09-27 Univ Massachusetts Closed-ended linear duplex dna for non-viral gene transfer
KR20190100318A (ko) * 2016-12-30 2019-08-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 페닐케톤뇨증을 치료하기 위한 유전자 치료
US20200056190A1 (en) * 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
CA3057142A1 (en) * 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
WO2018222925A1 (en) * 2017-05-31 2018-12-06 Ultragenyx Pharmaceutical Inc. Therapeutics for phenylketonuria
EP3665289A1 (de) * 2017-08-09 2020-06-17 Bioverativ Therapeutics Inc. Nukleinsäuremoleküle und verwendungen davon

Also Published As

Publication number Publication date
AU2020235121A1 (en) 2021-11-04
EP3938515A2 (de) 2022-01-19
CA3133330A1 (en) 2020-09-17
KR20210149702A (ko) 2021-12-09
EP3938515A4 (de) 2022-12-28
IL286283A (en) 2021-10-31
US20230024354A1 (en) 2023-01-26
MX2021011037A (es) 2021-12-15
WO2020186150A3 (en) 2020-10-29
BR112021017852A2 (pt) 2021-11-30
JP2022525302A (ja) 2022-05-12
WO2020186150A2 (en) 2020-09-17
CN113874508A (zh) 2021-12-31

Similar Documents

Publication Publication Date Title
IL286283A (en) Non-viral DNA vectors and their uses for therapeutic expression of phenylalanine hydroxylase (pah)
EP3463897A4 (de) Digitaldruckverfahren und -system
EP3931360A4 (de) Systeme und verfahren zur verwendung von sequenzierungsdaten zur pathogendetektion
EP3715461A4 (de) Genom-editing-zusammensetzung unter verwendung von crispr/cpf1-system und verwendung davon
EP3371194A4 (de) Proteinsequenzierungsverfahren und reagenzien
EP3436576A4 (de) Zelllinie für rekombinante protein- und/oder virusvektorproduktion
EP3686275A4 (de) Gen-editierende t-zelle und verwendung davon
EP3662079A4 (de) Verfahren zur detektion von modifizierter und nichtmodifizierter dna
EP3310919A4 (de) Vektoren zur verwendung in einem induzierbaren koexpressionssystem
EP3359671A4 (de) Dna-vektoren, transposons und transposasen für eukaryontische genommodifikation
IL284687A (en) Novel fusion proteins specific for CD137 and GPC3
EP3735420A4 (de) Einzeldomänenantikörper-zytosindeaminase-fusionsproteine
EP3565563A4 (de) Nukleinsäuren und verfahren zur genom-editierung
EP4031168A4 (de) Synthetische dns-vektoren und verwendungsverfahren
IL289254A (en) Systems and methods for preparing samples, tiling samples, and correcting deviation and quality control of tiling data
EP3997205A4 (de) Dna-sequenzierungsverfahren
EP3504280A4 (de) Selektiver matter und glänzender druck
EP3331653A4 (de) Spotglanz und glanzkontrolle in einem tintenstrahldrucksystem
IL286284A (en) Non-viral DNA vectors and their uses for therapeutic expression fviii
EP2232258A4 (de) Verbesserte virale proteinquantifizierung und impfstoffqualitätskontrolle damit
EP3910066A4 (de) Dna-referenzstandard und seine verwendung
EP3246406A4 (de) Genexpressionssystem mit verwendung von flüchtiger rna und genindroduktions-/-expressionsvektor mit besagter rna
EP3476945A4 (de) Kit und verfahren zur rna-detektion
EP4000220A4 (de) Verfahren und vorrichtung zur strommessung und strombegrenzung
EP3491009A4 (de) Proteinexpressionsverstärkersequenzen und verwendung davon